<SEC-DOCUMENT>0001279569-19-000970.txt : 20190425
<SEC-HEADER>0001279569-19-000970.hdr.sgml : 20190425
<ACCEPTANCE-DATETIME>20190425100237
ACCESSION NUMBER:		0001279569-19-000970
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190425
FILED AS OF DATE:		20190425
DATE AS OF CHANGE:		20190425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		19765871

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of April 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBITS INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 94%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;<A HREF="ex991.htm">ESSA Pharma to Attend Bloom Burton &amp; Co. Healthcare Investor Conference 2019</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: April 25, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED APRIL 25, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="essalogo.jpg" ALT="" STYLE="width: 190px; height: 90px">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Pharma to Attend Bloom Burton &amp;
Co. Healthcare Investor Conference 2019</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">HOUSTON and VANCOUVER, April 25, 2019 /CNW/
-&nbsp;<B>ESSA Pharma Inc. </B>(TSX-V: EPI; Nasdaq: EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;), a pharmaceutical company
focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton
&amp; Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre&nbsp;in
Toronto, Ontario, Canada.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Dr. Parkinson will provide a corporate overview
of the Company's business and will be available for one-on-one meetings from April 29 &ndash; May 1, 2019.&nbsp; ESSA's Chief Financial
Officer, David S. Wood, and Chief Operating Officer, Peter Virsik, will also be in attendance</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The presentation will be webcast live.&nbsp;To
access the webcast, please visit http://wsw.com/webcast/bloomburton4/epi/. The webcast replay will remain available on the Company's
website (www.essapharma.com) for 90 days following the live presentation.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>Presentation Details&nbsp;:</U></B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Event:&nbsp;Bloom Burton &amp; Co. Healthcare
Investor Conference 2019<BR>
Presentation Date:&nbsp;Wednesday, May 1, 2019<BR>
Presentation Time:&nbsp;10:30am Eastern Standard Time<BR>
Location:&nbsp;Metro Toronto Convention Centre, Toronto, Ontario, Canada<BR>
URL:&nbsp;http://wsw.com/webcast/bloomburton4/epi/</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.</B><BR>
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant
prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current therapies. ESSA believes
that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit
from hormone-based therapies, by disrupting the androgen receptor (&quot;AR&quot;) signaling pathway that drives prostate cancer
growth and by preventing AR transcriptional activity by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the AR.
A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability
to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA proprietary compounds, otherwise known
as aniten compounds, bind to the N-terminal domain of the androgen receptor (&quot;AR&quot;).&nbsp; The company is currently conducting
studies on a small number of next generation compounds with higher potency and metabolic stability, longer half-life and superior
pharmaceutical properties.&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About the Conference: </B><BR>
The Bloom Burton &amp; Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested
in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from
the premier Canadian publicly traded and private companies through presentations and private meetings.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Bloom Burton &amp; Co.: </B><BR>
Bloom Burton &amp; Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for
both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets
professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our
clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&amp;A advisory,
equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation
services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is
also a member of the Canadian Investor Protection Fund (CIPF).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Prostate Cancer</B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease, metastatic CPRC (&quot;mCRPC&quot;), and most patients ultimately
succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional
treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including
abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally
experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both
in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking
tumor growth when current therapies are no longer effective.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B><BR>
This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;look forward&quot;, &quot;anticipate&quot; and, &quot;believe&quot;, and statements that an action or event
&quot;is expected&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and includes,
but is not limited to, statements regarding timing of identifying the next-generation aniten product candidate, the anticipated
timing of submitting an Investigational New Drug Application to the US Food and Drug Administration and beliefs as to ESSA's proprietary
compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and economic conditions.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 13, 2018 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made
and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances
should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against
attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content:http://www.prnewswire.com/news-releases/essa-pharma-to-attend-bloom-burton--co-healthcare-investor-conference-2019-300837935.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content: http://www.newswire.ca/en/releases/archive/April2019/25/c7397.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Company Contact: David S. Wood, ESSA
Pharma Inc., Contact: (778) 331-0962; Investor Relations Contact: Alan Lada, Solebury Trout, Contact: (617) 221-8006, Email: alada@soleburytrout.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 07:30e 25-APR-19</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJM&=)VD=5'$0JJ\2W11161L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?*NI?\A:]_Z^)/\ T(U]55\JZE_R%KW_
M *^)/_0C7IY9O+Y'DYKM'YE:BBKFEZ9=ZSJ4.GV2*]S,2$5F"@X!)Y/L#7K-
MI*[/&2;=D4Z*[+_A5GBS_GR@_P# E*/^%6>+/^?*#_P)2LOK%'^9&WU6M_*S
MC:*[+_A5GBS_ )\H/_ E*/\ A5GBS_GR@_\  E*/K%'^9!]5K?RLXVBNR_X5
M9XL_Y\H/_ E*/^%6>+/^?*#_ ,"4H^L4?YD'U6M_*SC:](^#'_(R:A_UZ?\
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MY'SA17H^K?![5K8L^EWD%['V23]V_P#@?S%<5J/A[6=()%_IEU !_&T9*_\
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MB;GDOQEUO+V.AQ-P/])G /U"#_T(_E7E%:?B+5WU[Q#?:DV<3RDH#V0<*/R
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MJ<ZZGNY;5YJ?(^A)1117 >D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[6_V3WKYQU72KW1=0DL=0@:&=.H/1AZ@]P?6OJ>LCQ!X:TSQ+9?9M1@#[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
